Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist
2005; Wiley; Volume: 45; Issue: 3 Linguagem: Inglês
10.1111/j.1537-2995.2005.04222.x
ISSN1537-2995
AutoresW. Conrad Liles, Elin Rodger, Hal E. Broxmeyer, Christine Dehner, Karin Badel, Gary Calandra, Jeff Christensen, Brent L. Wood, Thomas H. Price, David C. Dale,
Tópico(s)Chemokine receptors and signaling
ResumoBACKGROUND: AMD3100, a selective antagonist of CXCR4, rapidly mobilizes CD34+ hematopoietic progenitor cells (HPCs) from marrow to peripheral blood with minimal side effects. STUDY DESIGN AND METHODS: To further investigate potential clinical utility of AMD3100 for CD34+ cell mobilization and collection, a Phase I study in normal volunteers was performed examining single‐dose administration of AMD3100 alone and in combination with a standard 5‐day granulocyte–colony‐stimulating factor (G–CSF) regimen. RESULTS: AMD3100 (160 µg/kg × 1 on Day 5) significantly increased both G–CSF‐stimulated (10 µg/kg/day) mobilization of CD34+ cells (3.8‐fold) and leukapheresis yield of CD34+ cells. Moreover, collection of CD34+ cells was comparable between individuals mobilized by a single‐dose regimen of AMD3100 (240 µg/kg) and individuals mobilized with a 5‐day regimen of G–CSF. AMD3100‐mobilized leukapheresis products contained significantly greater numbers of T and B cells compared to G–CSF‐stimulated leukapheresis products. CONCLUSION: These findings indicate that AMD3100 can be used alone or as an adjunct to G–CSF to mobilize cells for HPC transplantation.
Referência(s)